Shabto, Julie M <br/><br/>
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors.  [electronic resource] 

 -  Cancer medicine  04 2020 
 - 2752-2760 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.2932  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immune Checkpoint Inhibitors--therapeutic use<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Retrospective Studies<br/>Risk Assessment--methods<br/>Risk Factors<br/>Survival Rate<br/>Urologic Neoplasms--drug therapy